Article info

Download PDFPDF

Original research
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Authors

  1. Correspondence to Dr Christopher T Ritchlin; Christopher_Ritchlin{at}URMC.Rochester.edu
View Full Text

Citation

Ritchlin CT, Helliwell PS, Boehncke W, et al
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Publication history

  • Received September 29, 2020
  • Revision received November 24, 2020
  • Accepted December 3, 2020
  • First published February 10, 2021.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.